Life Insurance Corporation of India

LICI.NS plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LICI.NS stands at 5.5T. In comparison, LICI.BO has a market cap of 5.5T. Regarding current trading prices, LICI.NS is priced at ₹882.00, while LICI.BO trades at ₹881.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LICI.NS currently has a P/E ratio of 10.44, whereas LICI.BO's P/E ratio is 10.82. In terms of profitability, LICI.NS's ROE is +0.18%, compared to LICI.BO's ROE of +0.18%. Regarding short-term risk, LICI.NS is less volatile compared to LICI.BO. This indicates potentially lower risk in terms of short-term price fluctuations for LICI.NS.Check LICI.BO's competition here

LICI.NS plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LICI.NS stands at 5.5T. In comparison, SBILIFE.NS has a market cap of 2.1T. Regarding current trading prices, LICI.NS is priced at ₹882.00, while SBILIFE.NS trades at ₹2,082.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LICI.NS currently has a P/E ratio of 10.44, whereas SBILIFE.NS's P/E ratio is 84.02. In terms of profitability, LICI.NS's ROE is +0.18%, compared to SBILIFE.NS's ROE of +0.14%. Regarding short-term risk, LICI.NS is less volatile compared to SBILIFE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for LICI.NS.Check SBILIFE.NS's competition here

LICI.NS plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LICI.NS stands at 5.5T. In comparison, SBILIFE.BO has a market cap of 2.1T. Regarding current trading prices, LICI.NS is priced at ₹882.00, while SBILIFE.BO trades at ₹2,083.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LICI.NS currently has a P/E ratio of 10.44, whereas SBILIFE.BO's P/E ratio is 84.00. In terms of profitability, LICI.NS's ROE is +0.18%, compared to SBILIFE.BO's ROE of +0.14%. Regarding short-term risk, LICI.NS is less volatile compared to SBILIFE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for LICI.NS.Check SBILIFE.BO's competition here

LICI.NS plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LICI.NS stands at 5.5T. In comparison, HDFCLIFE.BO has a market cap of 1.6T. Regarding current trading prices, LICI.NS is priced at ₹882.00, while HDFCLIFE.BO trades at ₹735.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LICI.NS currently has a P/E ratio of 10.44, whereas HDFCLIFE.BO's P/E ratio is 84.03. In terms of profitability, LICI.NS's ROE is +0.18%, compared to HDFCLIFE.BO's ROE of +0.11%. Regarding short-term risk, LICI.NS is less volatile compared to HDFCLIFE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for LICI.NS.Check HDFCLIFE.BO's competition here

LICI.NS plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LICI.NS stands at 5.5T. In comparison, HDFCLIFE.NS has a market cap of 1.6T. Regarding current trading prices, LICI.NS is priced at ₹882.00, while HDFCLIFE.NS trades at ₹734.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LICI.NS currently has a P/E ratio of 10.44, whereas HDFCLIFE.NS's P/E ratio is 84.12. In terms of profitability, LICI.NS's ROE is +0.18%, compared to HDFCLIFE.NS's ROE of +0.11%. Regarding short-term risk, LICI.NS is less volatile compared to HDFCLIFE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for LICI.NS.Check HDFCLIFE.NS's competition here

LICI.NS plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LICI.NS stands at 5.5T. In comparison, ICICIPRULI.BO has a market cap of 968.8B. Regarding current trading prices, LICI.NS is priced at ₹882.00, while ICICIPRULI.BO trades at ₹660.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LICI.NS currently has a P/E ratio of 10.44, whereas ICICIPRULI.BO's P/E ratio is 70.79. In terms of profitability, LICI.NS's ROE is +0.18%, compared to ICICIPRULI.BO's ROE of +0.11%. Regarding short-term risk, LICI.NS is more volatile compared to ICICIPRULI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LICI.NS.Check ICICIPRULI.BO's competition here

LICI.NS plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LICI.NS stands at 5.5T. In comparison, ICICIPRULI.NS has a market cap of 967.7B. Regarding current trading prices, LICI.NS is priced at ₹882.00, while ICICIPRULI.NS trades at ₹661.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LICI.NS currently has a P/E ratio of 10.44, whereas ICICIPRULI.NS's P/E ratio is 70.64. In terms of profitability, LICI.NS's ROE is +0.18%, compared to ICICIPRULI.NS's ROE of +0.11%. Regarding short-term risk, LICI.NS is more volatile compared to ICICIPRULI.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LICI.NS.Check ICICIPRULI.NS's competition here

LICI.NS plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LICI.NS stands at 5.5T. In comparison, MFSL.NS has a market cap of 640.1B. Regarding current trading prices, LICI.NS is priced at ₹882.00, while MFSL.NS trades at ₹1,841.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LICI.NS currently has a P/E ratio of 10.44, whereas MFSL.NS's P/E ratio is 431.33. In terms of profitability, LICI.NS's ROE is +0.18%, compared to MFSL.NS's ROE of +0.02%. Regarding short-term risk, LICI.NS is more volatile compared to MFSL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LICI.NS.Check MFSL.NS's competition here

LICI.NS plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LICI.NS stands at 5.5T. In comparison, MFSL.BO has a market cap of 639.7B. Regarding current trading prices, LICI.NS is priced at ₹882.00, while MFSL.BO trades at ₹1,841.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LICI.NS currently has a P/E ratio of 10.44, whereas MFSL.BO's P/E ratio is 431.03. In terms of profitability, LICI.NS's ROE is +0.18%, compared to MFSL.BO's ROE of +0.02%. Regarding short-term risk, LICI.NS is less volatile compared to MFSL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for LICI.NS.Check MFSL.BO's competition here

LICI.NS plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LICI.NS stands at 5.5T. In comparison, NIVABUPA.NS has a market cap of 141.2B. Regarding current trading prices, LICI.NS is priced at ₹882.00, while NIVABUPA.NS trades at ₹76.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LICI.NS currently has a P/E ratio of 10.44, whereas NIVABUPA.NS's P/E ratio is 152.88. In terms of profitability, LICI.NS's ROE is +0.18%, compared to NIVABUPA.NS's ROE of -0.00%. Regarding short-term risk, LICI.NS is less volatile compared to NIVABUPA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for LICI.NS.Check NIVABUPA.NS's competition here

LICI.NS plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LICI.NS stands at 5.5T. In comparison, RELIGARE.BO has a market cap of 68.5B. Regarding current trading prices, LICI.NS is priced at ₹882.00, while RELIGARE.BO trades at ₹210.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LICI.NS currently has a P/E ratio of 10.44, whereas RELIGARE.BO's P/E ratio is 66.61. In terms of profitability, LICI.NS's ROE is +0.18%, compared to RELIGARE.BO's ROE of +0.03%. Regarding short-term risk, LICI.NS is less volatile compared to RELIGARE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for LICI.NS.Check RELIGARE.BO's competition here